ArticleThe Journal of allergy and clinical immunology2015
D prostanoid receptor 2 (chemoattractant receptor-homologous molecule expressed on TH2 cells) protein expression in asthmatic patients and its effects on bronchial epithelial cells.
Article in The Journal of allergy and clinical immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 53 citations in OpenAlex.
- Epithelial-immune interactions govern type 2 immunity at barrier surfaces.Current opinion in immunology · 2024Review
- High PGDBritish journal of cancer · 2022Article
- The CRTh2 polymorphism rs533116 G > A associates with asthma severity in older females.Frontiers in medicine · 2022Article
- Sanzi Yangqin Decoction Alleviates Allergic Asthma by Modulating Th1/Th2 Balance: Coupling Network Pharmacology with Biochemical Pharmacology.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Prostaglandin regulation of type 2 inflammation: From basic biology to therapeutic interventions.European journal of immunology · 2021Review
- The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy.International journal of molecular sciences · 2020Review
- The Dynamics of the Skin's Immune System.International journal of molecular sciences · 2019Review
- Prostaglandins in asthma and allergic diseases.Pharmacology & therapeutics · 2019Review
- The prostaglandin DRespiratory research · 2018Review
- TNature reviews. Immunology · 2018Review
- The therapeutic potential of CRTH2/DP2 beyond allergy and asthma.Prostaglandins & other lipid mediators · 2017Review
- CRTH2 antagonists in asthma: current perspectives.Clinical pharmacology : advances and applications · 2017Review
- Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory Disease.Immunology and allergy clinics of North America · 2016Review
- Eosinophil production of prostaglandin DThe Journal of allergy and clinical immunology · 2016Article
- Future treatment for asthma.European respiratory review : an official journal of the European Respiratory Society · 2016Article
- Activated prostaglandin D2 receptors on macrophages enhance neutrophil recruitment into the lung.The Journal of allergy and clinical immunology · 2016Article
- Allergen-encoded signals that control allergic responses.Current opinion in allergy and clinical immunology · 2016Review
- Immune Modulation in Asthma: Current Concepts and Future Strategies.Respiration; international review of thoracic diseasesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe D prostanoid receptor 2 (DP2; also known as chemoattractant receptor-homologous molecule expressed on TH2 cells) is implicated in the pathogenesis of asthma, but its expression within bronchial biopsy specimens is unknown.
objectivesWe sought to investigate the bronchial submucosal DP2 expression in asthmatic patients and healthy control subjects and to explore its functional role in epithelial cells.
methodsDP2 protein expression was assessed in bronchial biopsy specimens from asthmatic patients (n = 22) and healthy control subjects (n = 10) by using immunohistochemistry and in primary epithelial cells by using flow cytometry, immunofluorescence, and quantitative RT-PCR. The effects of the selective DP2 agonist 13, 14-dihydro-15-keto prostaglandin D2 on epithelial cell migration and differentiation were determined.
resultsNumbers of submucosal DP2(+) cells were increased in asthmatic patients compared with those in healthy control subjects (mean [SEM]: 78 [5] vs 22 [3]/mm(2) submucosa, P < .001). The bronchial epithelium expressed DP2, but its expression was decreased in asthmatic patients compared with that seen in healthy control subjects (mean [SEM]: 21 [3] vs 72 [11]/10 mm(2) epithelial area, P = .001), with similar differences observed in vitro by primary epithelial cells. Squamous metaplasia of the bronchial epithelium was increased in asthmatic patients and related to decreased DP2 expression (rs = 0.69, P < .001). 13, 14-Dihydro-15-keto prostaglandin D2 promoted epithelial cell migration and at air-liquid interface cultures increased the number of MUC5AC(+) and involucrin-positive cells, which were blocked with the DP2-selective antagonist AZD6430.
conclusionsDP2 is expressed by the bronchial epithelium, and its activation drives epithelial differentiation, suggesting that in addition to its well-characterized role in inflammatory cell migration, DP2 might contribute to airway remodeling in asthmatic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.